Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000723467 | SCV000109865 | pathogenic | not provided | 2012-10-08 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000078027 | SCV000486451 | likely pathogenic | Citrullinemia type I | 2016-06-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001290025 | SCV000816577 | pathogenic | Citrullinemia | 2023-10-15 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 279 of the ASS1 protein (p.Arg279Gln). This variant is present in population databases (rs371265106, gnomAD 0.01%). This missense change has been observed in individual(s) with citrulllinemia type I (PMID: 9090528, 16475226, 23099195; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 92375). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. For these reasons, this variant has been classified as Pathogenic. |
ARUP Laboratories, |
RCV000723467 | SCV000883418 | likely pathogenic | not provided | 2017-05-03 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000078027 | SCV001520228 | pathogenic | Citrullinemia type I | 2024-02-29 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000078027 | SCV002808243 | pathogenic | Citrullinemia type I | 2021-07-20 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000078027 | SCV004238479 | likely pathogenic | Citrullinemia type I | 2023-04-06 | criteria provided, single submitter | clinical testing |